Skip to main
  1. Stocks
  2. Inhibrx Biosciences Inc
  3. Forecast
INBX

INBX Stock Forecast & Price Target

INBX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inhibrx Biosciences is viewed positively because its proprietary multivalent protein-engineering platform is producing clinically differentiated data where earlier DR5 and OX40 approaches often failed, supporting the idea that its candidates better balance potency and safety. Ozekibart showed a 52% reduction in the risk of progression or death, more than doubled median PFS to 5.52 months versus 2.66 months, and has an FDA-accepted BLA with a PDUFA date of April 14, 2027, while INBRX-106 lifted cORR to 44.0% versus 21.4% for Keytruda alone. Despite a 3Q26 net loss of $2.46 per share and cash of about $199.5 million, the balance sheet appears strong enough to fund multiple catalysts, with R&D and SG&A of $26.0 million and $7.8 million, respectively.

Bears say

Inhibrx Biosciences is viewed negatively because it has never been profitable and continues to post sizable losses, with net loss per share figures including (2.80), (1.85), and (9.04), underscoring a business model that has not yet proven self-sustaining. The company may need to raise additional capital to fund operations, and if it cannot secure financing, it faces going-concern risk, which materially weakens the investment case. It also competes in the increasingly crowded bispecific construct arena against better-resourced rivals, and even encouraging initial data may not be enough if future clinical results fail to differentiate the pipeline.

INBX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

INBX Analyst Forecast & Price Prediction

Get the latest INBX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in INBX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inhibrx Biosciences Inc (INBX) Forecast

Analysts have given INBX a Strong Buy based on their latest research and market trends.

According to 2 analysts, INBX has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $185, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $185, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inhibrx Biosciences Inc (INBX)


INBX Analyst Forecast & Price Prediction

Get the latest INBX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in INBX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INBX stock data and trends